FDA 483 - Mehrnaz Hojjati MD - August 26, 2021

An FDA inspection of Mehrnaz Hojjati MD in Loma Linda, CA, a clinical investigator, revealed significant deviations from the investigational plan and protocol. The firm enrolled subjects using an expired protocol and failed to ensure subjects received all required tests. Additionally, protocol deviations were not reported in a timely manner.